(PharmaNewsWire.Com, July 17, 2017 ) According to the report “Europe Checkpoint Inhibitors", published by Market Data Forecast, the global market is projected to reach USD 5.43 billion by 2021, at a CAGR of 28% from 2016 to 2021.
Europe Checkpoint Inhibitors Market are drugs used in Immunotherapy to let immune system attack cancer cells by blocking checkpoint molecules. Checkpoint molecules are produced by immune system to avoid damage to the normal cells from immune system’s attack on infected cells. But, Cancer cells use these molecules to escape immune system. By blocking these checkpoint molecules, Checkpoint inhibitors helps immune system detect and attack cancer cells.
The immune system of human body depends on multiple checkpoints or immunological breaks, which avoid over-activation of the healthy cells or immune system. Tumor or cancerous cells often take advantage of these checkpoints to escape detection and fight against immune system. To struggle against such cancer cells, the focus of the scientists and drug developers is gradually diverting towards immunotherapeutics, which makes use of the body’s own immune system or its components to fight cancer. The developers have attained successful results with targeted based therapeutics including conjugated and monoclonal antibodies, but there has been a surge of interest in other classes of immunotherapeutics to treat and manage cancer, including immune checkpoint inhibitors, whole cell based therapies and therapeutic cancer vaccines.
Europe Checkpoint Inhibitors market: Drivers & Restraints
Rising Prevalence of cancer, and increasing funding and government support towards developing new drugs are some of the factors driving the growth of the market? However, high expenses involved in R&D activities is one of the major factors restricting the growth of the market.
CTLA-4 Segment holds the highest share accounting for almost 94 % of the overall market. However, this segment is expected to lose some of its market to PD-1 inhibitors segment during the forecast period as majority of new treatments is based on PD-1 inhibitors. CLTA-4 is aberrantly up-regulated and is present of the surface of T cells in certain cancer, dampening T-cell activation in response to the tumor cells while PD-1 inhibits T-cell function assisting tumor’s ability to invade the immune system. Inhibiting a checkpoint enhance the anti-tumor T-cell response, which results in destruction of cancerous cells. Many giant players worldwide are performing clinical trials with the help of these two immune checkpoint inhibitors and are expected to show positive results during the forecast period.
For instance, Pfizer, Inc. in collaboration with the University of Pittsburgh is performing phase 2 clinical trials with Anti-CTLA4 monoclonal antibody to cure recurrent inoperable stage III or stage IV melanoma. Likewise, many other market players are performing clinical trials with CLTA-4 and PD-1 inhibitors and on the basis of previous results, is has been estimated that the molecules are expected to generate few efficient drugs for cancer treatment. In addition to these, many market players have developed some novel immune checkpoint inhibitors which include Elotuzumab, INCB024360, Indoximod, and Lirilumab.
Europe Checkpoint Inhibitors market: Region-wise Outlook
Geographically, market is further segmented into UK, France, Italy, Spain and Germany. Europe is the second largest market globally owing to the high funding available for clinical trials. Europe is anticipated to be the fastest developing regional section and will hold its position over the forecast period.
Key Questions Answered
• What is the current and future Europe Checkpoint Inhibitors market outlook in global? What trends are affecting the Europe market?
• What is the competitive landscape and market share of major players in the Checkpoint Inhibitors space in Europe?
• What are the key, high growth markets that Europe Checkpoint Inhibitors manufacturers should expand into? Which market segments are growing the fastest?
• What are the unmet needs with the Europe Checkpoint Inhibitors currently on the market? How will emerging technologies fulfil these unmet needs?
• What is physician perception and market outlook of Europe Checkpoint Inhibitors?
• What are the challenges and barriers that have hindered widespread adoption of Europe Checkpoint Inhibitors?
Europe Checkpoint Inhibitors market: Key Players
Some of the key players in the Europe checkpoint inhibitors market are Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma.
Reasons to buy Europe Checkpoint Inhibitors market Report:
• Global, regional and country-level analysis and forecasts of the study market; providing Insights on the geographical areas in which this industry is prospering
• Segment-level analysis on basis of product type, application, colour along with market size forecasts and y-o-y estimations to detect key areas of industry growth in detail
• Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
• Study of macro and micro environmental factors that affect the market presented in an extensive strategic analyses section containing PESTLE and Porter’s Five Forces Analyses
• A comprehensive listing of key market players along with company overview, product portfolios, key financial information (subjected to availability), SWOT analysis and Analyst overview to study and sustain the market environment
• Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
• Expertly devised Market Outlook along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
Checkout other related studies in the Diagnostics Segment:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: